1. Discovery of a Novel Mycobacterial F‐ATP Synthase Inhibitor and its Potency in Combination with Diarylquinolines
- Author
-
Patcharaporn Sae-Lao, Wuan Geok Saw, Chaudhari Namrata Pradeep, Anders Poulsen, Jocelyn Hui Ling Tan, Jickky Palmae Sarathy, Pearly Shuyi Ng, Gerhard Grüber, Peter Dröge, Revathy Kalyanasundaram, Pattarakiat Seankongsuk, Priya Ragunathan, Sivaraj Anbarasu, Umayal Lakshmanan, Harshyaa Makhija, Roderick W. Bates, Kevin Pethe, Krupakar Parthasarathy, Thomas Dick, Amaravadhi Harikishore, Adam Hotra, Joon Shin, Nitin Pal Kalia, School of Biological Sciences, School of Physical and Mathematical Sciences, Lee Kong Chian School of Medicine (LKCMedicine), Interdisciplinary Graduate School (IGS), and Nanyang Institute of Technology in Health and Medicine
- Subjects
Enzyme complex ,medicine.drug_class ,Microbial Sensitivity Tests ,010402 general chemistry ,Antimycobacterial ,01 natural sciences ,Catalysis ,chemistry.chemical_compound ,Structure-Activity Relationship ,Bacterial Proteins ,Drug Discovery ,medicine ,Structure–activity relationship ,Humans ,Diarylquinolines ,Enzyme Inhibitors ,Embryonic Stem Cells ,chemistry.chemical_classification ,Reporter gene ,ATP synthase ,biology ,Molecular Structure ,010405 organic chemistry ,Drug discovery ,Drug Synergism ,General Chemistry ,Mycobacterium tuberculosis ,General Medicine ,0104 chemical sciences ,ATP Synthesis ,Enzyme ,Pyrimidines ,chemistry ,Biochemistry ,Bacterial Proton-Translocating ATPases ,Biological sciences::Biochemistry [Science] ,Benzamides ,biology.protein ,Bedaquiline - Abstract
The F1 FO -ATP synthase is required for growth and viability of Mycobacterium tuberculosis and is a validated clinical target. A mycobacterium-specific loop of the enzyme's rotary γ subunit plays a role in the coupling of ATP synthesis within the enzyme complex. We report the discovery of a novel antimycobacterial, termed GaMF1, that targets this γ subunit loop. Biochemical and NMR studies show that GaMF1 inhibits ATP synthase activity by binding to the loop. GaMF1 is bactericidal and is active against multidrug- as well as bedaquiline-resistant strains. Chemistry efforts on the scaffold revealed a dynamic structure activity relationship and delivered analogues with nanomolar potencies. Combining GaMF1 with bedaquiline or novel diarylquinoline analogues showed potentiation without inducing genotoxicity or phenotypic changes in a human embryonic stem cell reporter assay. These results suggest that GaMF1 presents an attractive lead for the discovery of a novel class of anti-tuberculosis F-ATP synthase inhibitors. National Research Foundation (NRF) Accepted version This research was supported by the National ResearchFoundation (NRF) Singapore,NRF Competitive Research Programme (CRP), Grant Award Number NRF-CRP18-2017-01. A. Hotra is grateful to receive an IGS PremiumScholarship,Institute of Technology in Health and Medicineat NTU,and J. P. Sarathy received aPhD scholarship from theSchool of Medicine,NUS,Singapore.Wethank Dr. YongxinLi for the X-ray crystallographic structure determinations.
- Published
- 2020
- Full Text
- View/download PDF